



## Molecular Research on Pulmonary Hypertension: Focus on the Microbiome and Inflammation

Guest Editor:

### Dr. Lan Zhao

1. Department of Medicine,  
Division of Pulmonary, Allergy  
and Critical Care Medicine,  
Stanford University, Stanford, CA  
94305, USA

2. Vera Moulton Wall Center for  
Pulmonary Vascular Disease,  
Stanford University, Stanford, CA  
94305, USA

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editor

Pulmonary arterial hypertension (PAH) is a life-threatening condition characterized by vascular remodeling and dysfunction in the lungs.

Recent culture-free microbiome studies based on high-throughput sequencing and functional metabolomics have and will continue to provide insights into the relationship between microbiome and PAH. Moreover, specific microbial biomarkers have been shown to have promising diagnostic and therapeutic benefits in patients with PAH. The Special Issue invites contributions investigating the molecular mechanisms involving the microbiome in PAH vascular remodeling and disease progression, as well as respiratory and cardiac dysfunctions associated with chronic hypoxia and inflammation. Both original experimental and clinical research and review papers are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)